Apollo Health Ventures

Exciting spotlight on our portfolio company Ochre Bio being featured on BBC’s Click. Lara Lewington visited their UK labs to have a look at their groundbreaking work in liver disease treatments using AI-driven drug discovery and innovative testing on non-transplantable human livers: https://lnkd.in/erU4xxUT The potential of the dark genome is enormous, with a recent analysis by PreScouter, Inc. predicting a market worth nearly $300 billion by 2033. Major players like Eli Lilly and Company and Bayer are heavily investing in this research to unlock new therapies for complex diseases, with our portfolio company, HAYA Therapeutics, leading advancements in this space: https://lnkd.in/dSXsaJPQ A recent study, led by researchers from The Jackson Laboratory, found that individual genetic factors may shape how effective caloric restriction is for extending lifespan in mice. This discovery could lead to tailored dietary strategies for longevity: https://lnkd.in/eC5Fi5k6 #ICYDK #ApolloVC #Lifespan #Healthspan #Longevity #VentureCapital

Meet us in Stockholm at the Bio Europe from November 4th – 6th. Our COO, Dr. Anela Vukoja, will attend the industry's largest gathering of biopharma professionals in Europe, organized by the EBD Group. Reach out if you are in town or let us know via email: info@apollo.vc #BIOEurope #ApolloVC #Healthspan #Longevity #LifescienceVC #VentureCapital

We are excited to share that Alexandra Sharon Bause, Co-Founder and Venture Partner at Apollo Health Ventures, recently took the stage at the Milken Institute Asia Summit in Singapore. In the panel, “From Lifespan to Healthspan: The New Frontier of Investment,” Alexandra joined global leaders to discuss how advancements in longevity science and healthspan investment are set to transform lives. She highlighted Apollo’s commitment to leveraging breakthrough discoveries in aging biology to develop therapies that improve both lifespan and healthspan, ensuring healthier, longer lives. A huge thanks to the panelists and moderator Diane Ty for the engaging discussion! You can now catch the full conversation here: https://lnkd.in/edxxMjz2 #MIGlobal #ApolloVC #Healthspan #Longevity #LifescienceVC #VentureCapital

Our Co-Founder and Venture Partner, Alexandra Sharon Bause, has shared an insightful article on LinkedIn Pulse that explores how personalized health will shape the future of longevity medicine. In her piece, she discusses the importance of using health data to tailor treatments to individual aging trajectories while balancing the need for patient privacy—as done by YEARS. With the right data foundations, we can significantly improve early detection and intervention for age-related diseases: https://lnkd.in/ev-FQT8D Researchers have developed MetaboAgeMort, a new metabolomic clock, co-authored by Joris Deelen, based on metabolomic profiles from over 239,000 participants in the UK Biobank. With 99 modifiable factors identified, it reveals connections between mortality and diseases, highlighting factors that cause different aging rates among individuals despite identical chronological ages: https://lnkd.in/eakz7cXi An article published in Nature talks about targeting cytokine networks in neuroinflammatory diseases such as multiple sclerosis (MS) and neurosarcoidosis, looking at the complex relationship between immune responses, neuroinflammation, and therapeutic interventions: https://lnkd.in/eaHK6x2V #ICYDK #ApolloVC #Lifespan #Healthspan #Longevity #VentureCapital

We’re excited to announce the launch of our portfolio company, Booster Therapeutics, which has secured $15 M in seed financing led by us and Novo Holdings. Booster is pioneering a new class of medicines that activate the body’s natural protein degradation machinery, offering a new way to address complex diseases such as Parkinson’s and Alzheimer’s. The team is leveraging its DGRADX™ platform to develop small molecules that directly activate 20S proteasomes, aiming to restore the body’s ability to clear disease-causing proteins. As a company emerging from our venture creation investment strategy, we are thrilled to support Booster Therapeutics's mission towards creating first-in-class therapies for neurodegenerative diseases. Read more about this exciting news in their press release: https://lnkd.in/eR8yb5Ev #ApolloVC #Healthspan #Longevity #LifescienceVC #VentureCapital

On my way to Lausanne for the Lausanne XI 2024 workshop, a gathering organized by the OECD - OCDE and supported by CEOi - Global CEO Initiative on Alzheimer's Disease, Alzheimer's Disease International and World Economic Forum. This event brings together leaders committed to advancing Alzheimer’s research and innovation. I’m looking forward to speaking on the panel, ‘Capital for the Cure: Investing in Alzheimer’s Innovations,’ alongside esteemed colleagues Laurence Barker from SV Dementia Discovery Fund (DDF), Niklas Blomberg from Innovative Health Initiative (IHI), and Philip Scheltens from EQT Life Sciences, moderated by Carlos Granda (Bristol Myers Squibb). Together, we’ll explore how strategic investments can accelerate breakthroughs in Alzheimer’s treatments. I’m eager to connect with others passionate about tackling neurodegenerative diseases and enhancing healthspan through innovative treatments. See you in Lausanne! #LausanneXI #ApolloVC #Healthspan #Longevity #LifescienceVC #VentureCapital

Our portfolio company, Thymofox, is making strides in understanding how aging affects the immune system. New research from their scientific co-founders at Fred Hutch Cancer Center reveals that aging cells create “black holes” within the thymus, resembling a dense mass of dysfunctional cells that hinder T-cell production and thymus regeneration: https://lnkd.in/dajU_krT BioAge Labs is set to make its Wall Street debut, with its investor prospectus officially dropping as it prepares to trade under the ticker BIOA. The company’s lead candidate, Azelaprag, is currently in two Phase 2 trials, where it’s being tested alongside established obesity treatments from Eli Lilly and Company and Novo Nordisk: https://lnkd.in/eJNx78cX Our portfolio company YEARS recently opened a new longevity clinic in Berlin, and the interest in healthspan optimization is growing worldwide. The New York Times highlights Equinox’s new membership program, ‘Optimize by Equinox,’ coaching to help members live longer and healthier lives. With detailed blood test analysis and tailored lifestyle guidance, it’s clear that investing in health and longevity is becoming a priority: https://lnkd.in/e6U2RqqX #ICYDK #ApolloVC #Lifespan #Healthspan #Longevity #VentureCapital

Last week, I had the privilege of attending the Milken Institute Asia Summit in Singapore and speaking alongside visionary leaders from around the world. During our panel, “From Lifespan to Healthspan: The New Frontier of Investment,” I had the opportunity to discuss how Apollo Health Ventures is investing in groundbreaking science targeting the biology of aging, with the goal of developing accessible solutions that promote healthier, longer lives. A huge shoutout to our moderator, Diane Ty, and my fellow panelists Craig McGee, Michael Clinton, and Chinta Bhagat for a dynamic discussion on longevity science, the promise of new therapeutics, and the economic and social benefits of extended healthspans: https://lnkd.in/d8DNd4Xn Singapore truly stands out as a country that not only recognizes the challenges of an aging population but is proactively driving innovation to ensure healthier, longer lives for its people. I was especially impressed by Mr. Ong Ye Kung from the Ministry of Health (Singapore), who shared his vision for implementing predictive preventive care in the coming years to address the complexities of aging. For anyone interested in discussing the future of biotech and medicine for healthy longevity, I’d love to connect! Milken Institute Future of Aging #MIAsiaSummit #Longevity #Healthspan #Biotech #AgingScience #Investment

Come see us tomorrow at the 11th Annual Healthtech Investment Forum by Sachs Associates. Our Partner Dr. Marianne Mertens will be Co-Chairing the panel “Mapping the Future of Global HealthTech” with Boris Bogdan (Amazon Web Services (AWS)). They will be exploring this topic with Andreas Wüpper (Fresenius Medical Care Ventures GmbH), Christian Schenk (Apposite Capital), Elie Lobel (RDS), Konrad Dobschuetz, and Sarah Des Rosiers (Novartis Foundation). Let us know if you want to meet up in Basel or email us at info@apollo.vc #Sachs_HTIF #ApolloVC #Healthspan #Longevity #LifescienceVC #VentureCapital

Meet our Associate Pascale Eede, PhD and Partner Jan Adams at next week’s Annual Biotech in Europe Forum by Sachs Associates from September 25th – 26th. This global industry event will bring together companies and industry professionals with investors to address investment challenges for 2024, partnering, and prospects for 2025. Let us know if you want to meet up in Basel or email us at info@apollo.vc #Sachs_BEF #ApolloVC #Healthspan #Longevity #LifescienceVC #VentureCapital